XPO1 and neoplasm: Consistently with previous works in different tumor type models [13, 17, 19, 21–23, 25], immunoblotting analysis revealed that nuclear XPO1/CRM1 expression progressively decreased after SINE treatment (Figure 2A and Supplementary Figure S4).